| There are several reasons why it's been the right rFVIII option for him |
View online |
|
|
|
|
| Esperoct® is used to treat and prevent or reduce the
number of bleeding episodes in people with hemophilia A. |
|
|
|
|
| Esperoct® offers flexible storage,a providing the convenience I need in my life right now. I'm a recent college grad who is working, playing basketball, and just generally trying to live an active lifestyle. The 22-hour average half-lifeb of Esperoct® helps give me high factor levels for longer,c providing the protection against bleeds that I need." |
|
|
Individual results may vary
|
|
|
|
Now, Bradley is spending more time on his interests and less time infusing.
|
|
|
|
aEsperoct® can be stored at up to 104°F for up to 3 months or 86°F for up to 12 months and up to 4 hours after reconstitution. This is not the complete Esperoct® Instructions for Use. Please refer to the Instructions for Use provided with the Prescribing Information.
|
|
bIn adults. Data shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.
|
|
cCompared with standard half-life products.
|
|
|
|
|
|
|
Growing up in Kenya, Bradley O. and his parents struggled to access appropriate treatment for his severe hemophilia A. But now that he's using Esperoct®, everything is different.
|
|
He's infusing less oftena than he did on SHLs and maintaining higher factor levels. Plus, his treatment is portable even in hot weather,b which is just what he needs as he starts life out on his own.
|
|
Today, Bradley's a recent college graduate spending more time on interests like dancing and music and less time infusing—and his parents couldn't be more proud.
|
|
|
|
|
|
aCompared to SHL products, 50% fewer infusions when administered every other day and 40% fewer when administered 3x weekly.
|
|
bEsperoct® can be stored at up to 104°F for up to 3 months or 86°F for up to 12 months and up to 4 hours after reconstitution. This is not the complete Esperoct® Instructions for Use. Please refer to the Instructions for Use provided with the Prescribing Information.
|
|
|
| Selected Important Safety Information |
| Who should not use Esperoct®? |
| |
• |
You should not use Esperoct® if you are allergic to factor VIII or
any of the other ingredients of Esperoct® or if you are allergic to
hamster proteins
|
|
|
What is the most important information I need to know about Esperoct®?
|
| |
• |
Do not attempt to do an infusion yourself unless you have been taught how by
your healthcare provider or hemophilia treatment center
|
|
| |
• |
Call your healthcare provider right away or get emergency treatment right away
if you get any signs of an allergic reaction, such as:
hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling
of the face
|
|
|
Please
click here
or scroll below for additional Important Safety Information.
|
|
|
| Why Esperoct? |
| Among EHL products, fewer Esperoct® prescriptions were switched to another product.d |
|
|
Esperoct® keeps factor levels high for longere
|
|
Esperoct® keeps factor levels at or above 3% (moderate hemophilia) for 100% of the time in people 12 years or older who treat prophylacticallyf,g
|
|
|
|
|
|
Esperoct® may allow for fewer infusions per year compared to SHL products
|
|
Adults and adolescents require 50% fewer infusions if they previously infused every other day and 40% fewer infusions if they previously infused 3x/week.
|
|
|
|
|
|
|
dBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.
|
|
eCompared with standard half-life products.
|
|
fTrough level goal is 1% for prophylaxis.
|
|
gData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
|
|
|
The support you deserve at your fingertips
|
|
Get in touch with your local Hemophilia Community Liaison (HCL) for personalized support, tips and tools to help you manage life with hemophilia A, information about local events, and more.
|
|
|
|
|
| What is Esperoct®? |
| Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery |
| |
• |
Esperoct® is not used to treat von Willebrand Disease |
|
| Important Safety Information (cont’d) |
| What should I tell my healthcare provider before using Esperoct®? |
| |
• |
Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII |
| |
• |
Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct® |
|
| What are the possible side effects of Esperoct®? |
| |
• |
Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion |
|
| Please click here for Prescribing Information. |
| Esperoct® is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. |
| Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would
like to contact us, please click here or call 1-877-744-2579. |
| UNSUBSCRIBE
NOTICE |
| If you no longer
want to receive communications from Novo Nordisk, click
here to unsubscribe. You also may call us at 1-877-744-2579 or send us a
letter that includes your full contact information (eg, name, email address,
phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To
better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22ESP00032 July 2022 |
 |
|
|
|
